Sequential Precision Therapy Achieves 79-Month Survival in AFP-Producing Gastric Cancer with Dynamic HER2 Conversion
核心洞察
A 65-year-old patient with AFP-producing gastric cancer (搜索) achieved 79-month overall survival through sequential molecularly-guided therapy, demonstrating the potential for long-term outcomes in this aggressive disease subtype.
The case revealed dynamic HER2 (搜索) heterogeneity, with the primary tumor showing HER2 1+ expression that converted to HER2 3+ in metastatic lymph nodes after immunotherapy, highlighting the importance of repeat biopsies at disease progression.
Treatment with apatinib plus PD-1 inhibitor (搜索) achieved 27-month progression-free survival in the second-line setting, followed by successful third-line therapy with novel anti-HER2 (搜索) ADC DP303c after HER2 conversion was detected.
A remarkable case of AFP-producing gastric cancer (搜索) demonstrates how sequential precision therapy guided by dynamic biomarker monitoring can achieve exceptional survival outcomes, even in patients with this aggressive disease subtype. The case, reported by researchers from Liaoning Cancer Hospital (搜索), showcases a 79-month overall survival through strategic treatment sequencing and highlights the critical importance of HER2 (搜索) heterogeneity in treatment planning.
Exceptional Survival in Aggressive Disease Subtype
AFP-producing gastric cancer (搜索) (AFPGC) represents a rare and particularly aggressive variant, accounting for only 1.3-15% of gastric cancer (搜索) cases globally. This subtype is characterized by frequent liver metastasis (搜索), limited therapeutic options, and poor prognosis, with 5-year survival rates declining sharply from 45.8% in patients with AFP (搜索) <20 ng/mL to just 7.7% in those with AFP >300 ng/mL.
The 65-year-old male patient initially presented with gastric discomfort in January 2019. Gastroscopy revealed a mass in the gastric body and antrum, with histopathological confirmation of adenocarcinoma (搜索) showing HER2 (搜索) 1+ expression and intact mismatch repair proteins. Next-generation sequencing indicated microsatellite stable status with no ERBB2 amplification. The patient's serum AFP (搜索) was elevated at 516.5 ng/mL, confirming the AFPGC diagnosis.
Strategic Treatment Sequencing
First-line FLOT therapy (docetaxel, oxaliplatin, 5-fluorouracil) was initiated but disease progressed after seven cycles with new liver metastases, yielding a progression-free survival of 6 months. The patient then entered a clinical trial (NCT04006821) receiving apatinib plus a PD-1 inhibitor (搜索) as second-line therapy.
This combination achieved partial response after four cycles and sustained control for 27 months. The treatment demonstrated remarkable efficacy, with regression of liver and abdominal nodal lesions and normalized AFP (搜索) levels. Adverse events included grade 3 proteinuria and hypophysitis, both manageable with dose reduction and hormone replacement therapy.
Dynamic HER2 Heterogeneity Reveals New Therapeutic Target
In October 2021, disease progression was detected in left cervical, supraclavicular, and axillary lymph nodes while abdominal and primary lesions remained stable. Critically, a left cervical lymph node biopsy revealed metastatic gastric adenocarcinoma (搜索) with HER2 (搜索) 3+ expression, representing a dramatic conversion from the primary tumor's HER2 1+ status.
Next-generation sequencing confirmed ERBB2 amplification with a copy number of 37.3, indicating clear spatiotemporal HER2 (搜索) heterogeneity. This finding enabled targeted third-line therapy with DP303c, a novel anti-HER2 antibody-drug conjugate.
Novel ADC Therapy Achieves Sustained Response
Beginning in November 2021, the patient received five cycles of DP303c within a clinical trial (NCT04826107). Partial response was observed after two cycles, with rapid decline in serum AFP (搜索) from 195 ng/mL to 16.44 ng/mL after the first cycle and subsequent normalization.
Treatment was discontinued after the fifth cycle due to grade 3 neurotoxicity manifesting as persistent limb numbness, tingling, and restricted movement. Grade 2 ocular symptoms also occurred. Supportive care including neurotrophic agents, gabapentin, and traditional Chinese medicine acupuncture led to gradual neurological improvement over approximately two years.
Synergistic Mechanisms of Combination Therapy
The remarkable efficacy of apatinib plus PD-1 inhibitor (搜索) combination appears to result from synergistic mechanisms that remodel the tumor microenvironment. Anti-angiogenic agents targeting VEGF (搜索)/VEGFR2 (搜索) promote vascular normalization, alleviate hypoxia, and enhance CD8+ T cell infiltration while inducing high endothelial venules that support immune cell trafficking and activation.
These agents modulate the cytokine milieu by downregulating immunosuppressive factors such as HIF-1α and TGF-β, while enhancing cytotoxicity of CD8+ T cells and NK cells. They also reduce recruitment of M2-type tumor-associated macrophages and regulatory T cells, promoting M1 polarization and enhancing pro-inflammatory signaling including IFN-γ.
Understanding HER2 Conversion Mechanisms
The observed HER2 (搜索) conversion from negative to positive status following immunotherapy likely reflects multiple underlying mechanisms. Sustained immune pressure may drive selection of HER2-amplified clones with enhanced immune escape capabilities. Immune checkpoint inhibition remodels the tumor microenvironment, enabling cytokines such as IFN-γ and TNF-α to exert dual regulatory effects on HER2 expression.
Additional complexity arises from epigenetic mechanisms including promoter DNA methylation, histone modifications, and non-coding RNA regulation, along with signaling crosstalk and acquired mutations in genes such as PIK3CA. These mechanisms collectively enhance HER2 (搜索) expression plasticity under immunotherapeutic pressure.
Clinical Implications for Precision Medicine
This case emphasizes several critical clinical principles for managing HER2 (搜索)-positive gastric cancer (搜索). The documented HER2 heterogeneity and clonal evolution highlight the clinical value of repeat biopsy at progression to identify new targetable alterations. The combination of anti-angiogenic agents and immune checkpoint inhibitors demonstrates particular promise in AFPGC, achieving sustained response with manageable safety profile.
The sequential precision approach enabled long-term survival in refractory metastatic AFPGC, demonstrating the importance of dynamic biomarker-guided individualized treatment. Follow-up confirmed sustained partial response, normalized AFP (搜索), no endoscopic evidence of disease, and overall survival of 79 months with good quality of life.
Safety Considerations and Future Directions
While the novel anti-HER2 (搜索) ADC DP303c showed promising efficacy, treatment resulted in manageable but clinically significant ocular and neurological toxicities. This highlights the need for vigilant monitoring and multidisciplinary management to maintain therapeutic continuity.
The case demonstrates that combination anti-angiogenic and immunotherapy strategies can overcome baseline PD-L1 negativity and microsatellite stability by transforming the tumor immune microenvironment from an immune-excluded/desert to an immune-inflamed phenotype. This approach shows particular promise given the clinicopathological overlap between AFPGC and hepatocellular carcinoma.
Future research should focus on identifying optimal combination strategies and more reliable predictive biomarkers for this challenging patient population. The success of this sequential precision approach provides a framework for developing personalized treatment strategies in AFP-producing gastric cancer (搜索).